by Bioblast Editor | Feb 4, 2021 | Biosimilars updates
Roche reports a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER growth of Avastin (bevacizumab) was -25%, with the hematology franchise (including rituximab) at -22% and...
by Bioblast Editor | Feb 15, 2019 | Biosimilars updates
In its final appraisal of pertuzumab, the National Institute for Health and Care Excellence (NICE) has recommended it for the treatment of lympth node-positive disease. The final appraisal comes following the promise of a large discount offered by Roche.
by Bioblast Editor | Dec 17, 2018 | Biosimilars updates
NeuClone announces that it has biosimilar pertuzumab in preclinical development.
by Bioblast Editor | Aug 20, 2018 | Biosimilars updates
The National Institute for Health and Care Excellence (NICE) again recommends against Roche’s application for pertuzumab as an adjuvant treatment in patients with a high risk of recurrence. NICE confirmed its earlier findings that pertuzumab is unlikely to be...
by Bioblast Editor | Jun 15, 2018 | Biosimilars updates
The National Institute for Health and Care Excellence (NICE) rejects pertuzumab for adjuvant treatment of early breast cancer. The draft guidance reports that the drug may not extend patient’s lives and is not cost effective.
